Resistance to Molecular Therapies for Hepatocellular Carcinoma (Resistance to Targeted Anti-Cancer Therapeutics) 1st ed

  • NH_0000003722
23 $

by Augusto Villanueva (Editor)

Resistance to Molecular Therapies for Hepatocellular Carcinoma (Resistance to Targeted Anti-Cancer Therapeutics) 1st ed

by Augusto Villanueva (Editor)

 

This volume evaluates the clinical patterns of resistance to sorafenib, the impact of trial design in the second-line setting and the current gold standard to define radiological resistance; describes the molecular mechanisms responsible for treatment resistance in HCC patients, including components of the immune system and tumor microenvironment; determines the role of the cancer stem cell phenotype in resistance; reviews the experimental models to study resistance; and addresses new approaches to overcome resistance to sorafenib, using successful examples from other malignancies. 

 

Product details

  • Series: Resistance to Targeted Anti-Cancer Therapeutics (Book 13)
  • Hardcover: 147 pages
  • Publisher: Springer; 1st ed. 2017 edition (August 15, 2017)
  • Language: English